Trial reportBMC nephrology2025
Efficacy and safety of regional citrate anticoagulation using calcium-containing replacement solution in different modalities of continuous renal replacement therapy: a randomized controlled trial.
Trial report in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveRegional citrate anticoagulation (RCA) is recommended as the first choice of anticoagulation strategies in continuous renal replacement therapy (CRRT). However, when using calcium-containing replacement fluid, whether RCA can achieve sufficient anticoagulant effect among different CRRT modalities remains unclear. MATERIALS AND
methodsIn this open-label, three-arm, randomized trial, AKI patients receiving RCA-CRRT with calcium-containing replacement fluids were randomized to continuous veno-venous hemofiltration (CVVH), continuous veno-venous hemodialysis (CVVHD) and continuous veno-venous hemodiafiltration (CVVHDF) groups from 2022 to 2023. The primary outcomes were circuit lifespan and early circuit failure. Secondary endpoints included the safety of the three groups and 30-day all-cause mortality.
resultsA total of 121 patients were enrolled, with 40 in CVVH group, 40 in CVVHD group, and 41 in CVVHDF group. The circuit lifespan in CVVHDF group (70 h, IQR 65-72) was significantly longer than that in CVVHD (47 h, IQR 31.5-54) and CVVH group (64 h, IQR 46-71) (P < 0.001). Meanwhile, 27 circuits remained patent for 72 h (CVVH: 10/40, 25%; CVVHD: 1/40, 2.5%; CVVHDF: 16/41, 39.02%; P = 0.003). A significantly lower incidence of severe venous chamber thrombosis was observed in the CVVHDF group (2.4%, 1/41) relative to the CVVH (5%, 2/40) and CVVHD (50%, 20/40) groups (P < 0.001). Furthermore, early circuit failure (lifespan < 48 h) was observed in 35 circuits, occurring significantly more frequently in the CVVHD group (52.5%, 21/40) than in either the CVVH (22.5%, 9/40) or CVVHDF (12.2%, 5/41) groups (P = 0.004).
conclusionOur findings suggested that RCA-CRRT with calcium-containing replacement solution appeared to be safe and effective, with CVVHDF showing potentially prolonged filter survival compared to alternative modalities, which might support its consideration as a possible option in clinical practice.
trial registrationThis study was registered in the Chinese Clinical Trial Registry ( www.chictr.org.cn ) under the registration number ChiCTR2200061065 on 15 June 2022.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.